Bio News

Aribio Signs 203 Billion Won Global Option Deal for Alzheimer Disease Drug

Aribio has signed a global licensing option agreement with Fosun Pharma for its Alzheimer disease drug AR1001. The deal includes an 87 billion won upfront payment and 116 billion won upon exercise of the option. AR1001 is an oral PDE5 inhibitor taken once daily. The drug is curre

2026-05-14

Aptose relinquishes rights to 7.25 billion won blood cancer drug after Hanmi acquisition

Aptose has returned the rights to ‘CG-806,’ a blood cancer drug candidate in which it invested $5 million (approximately 7.25 billion won), following its acquisition by Hanmi Pharmaceutical. The candidate, licensed in 2018, cannot undergo further development under the agreement w

2026-05-14

Regenxbio’s DMD Gene Therapy Trial Succeeds; Company to Seek FDA Accelerated Approval

Regenxbio will begin the FDA accelerated approval process after successfully completing a clinical trial of its gene therapy for Duchenne muscular dystrophy (DMD). The therapy was developed with the goal of achieving greater safety than a competing drug linked to two deaths, and

2026-05-14

Create Medicine Raises $122 Million to Accelerate CAR-T Clinical Development

Create Medicine has raised $12200 million (approximately 176.9 billion won) in new funding to advance clinical trials of its first CAR-T candidate. The company is developing a CAR-T therapy that uses myeloid cells to target solid tumors and recently expanded its research into aut

2026-05-14

‘Anchor’ technology traps drugs in solid tumors, increasing tumor-shrinking effects

A technology called the restricted interaction peptide (RIP) has been developed to trap drugs in solid tumors and enhance treatment effects. The technology responds to tumor enzymes to anchor drugs to cancer cells, and in animal studies, it reduced tumors when loaded with antican

2026-05-14

Bukwang Pharm Secures 28-Week Primate Data for RNA Drug CP-102

Bukwang Pharm subsidiary Contera Pharma has released 28-week long-term data from primates for CP-102, an RNA treatment for a rare disease. CP-012, a Parkinson disease treatment, achieved positive results in a phase 1b trial and is preparing for a subsequent phase 2 trial. Based o

2026-05-14

Oscotec Licenses Alzheimer Disease Drug Candidate to Sanofi for KRW 54.1 Billion

Oscotec has licensed ADEL-Y01, an Alzheimer disease drug candidate targeting tau protein, to Sanofi in a deal worth a total of KRW 54.1 billion. The agreement is a revenue-sharing arrangement through co-development partner ADEL, with Oscotec set to receive 47% of the total amount

2026-05-14

ToolGen Halts Development of Two Pipelines, Focuses on Cardiovascular Drug Candidate GEB-200

ToolGen is halting development of two pipelines and focusing on the cardiovascular drug candidate GEB-200. The discontinued TGT-001 was designated an orphan drug by the US FDA in 2023, while GEB-200 works by suppressing the LPA gene. The company plans to submit an investigational

2026-05-14

Handok Releases Phase 3 Topline Results for Rare Disease Drug ‘RZ358’ and Begins FDA Discussions

Global Phase 3 topline results for ‘RZ358,’ a rare disease drug licensed in by Handok, have been released, and discussions with the FDA on follow-up development have begun. The drug is being developed to treat congenital hyperinsulinism and was designated an FDA orphan drug in No

2026-05-14

Kyungdong Pharm completes phase 3 trial of combination therapy for benign prostatic hyperplasia targeting 300 billion won market

Kyungdong Pharm has completed a phase 3 trial of KDF1905, a combination therapy targeting the 300 billion won benign prostatic hyperplasia market, and is preparing to submit an application for approval. KDF1905 is an improved drug combining an alpha-1 blocker and a beta-3 agonist

2026-05-14